Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in HFpEF Exercise Capacity Study
NCT03877224Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Kansas City Cardiomyopathy Questionnaire-Total Symptom Score at 16 weeks, Kansas City Cardiomyopathy Questionnaire-Physical Limitation Score at 16 weeks and 1 more. Started Apr 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03877224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877224.